Brazil Antimicrobial Feed Additive Ban Spurs Phibro Response

Phibro Animal Health ( (PAHC) ) just unveiled an update.

On April 27, 2026, Brazil’s Ministry of Agriculture and Livestock issued Ordinance No. 1617, banning the import, manufacture, marketing and use of performance-enhancing feed additives containing medically important antimicrobials, including Phibro’s virginiamycin and bacitracin, after a 180-day transition period. Phibro is working with Brazilian regulators to shift virginiamycin toward therapeutic indications for cattle and broiler chickens, leveraging existing therapeutic claims for bacitracin and launching its PhibroVet digital prescription platform, and it currently expects only limited impact on its fiscal 2026 results from the regulatory change.

The most recent analyst rating on (PAHC) stock is a Hold with a $62.00 price target. To see the full list of analyst forecasts on Phibro Animal Health stock, see the PAHC Stock Forecast page.

Spark’s Take on PAHC Stock

According to Spark, TipRanks’ AI Analyst, PAHC is a Outperform.

The score is driven primarily by strong technical momentum and a bullish earnings update (raised guidance and strong segment performance). Financial performance is improving but constrained by leverage and historical volatility, while valuation is only fair with a modest dividend yield.

To see Spark’s full report on PAHC stock, click here.

More about Phibro Animal Health

Phibro Animal Health Corporation is a global diversified animal health and nutrition company that provides products and solutions to livestock producers, farmers, veterinarians and consumers caring for farm and companion animals. The company focuses on maintaining and enhancing animal health through feed additives, therapeutics and related technologies across key international markets.

Average Trading Volume: 292,156

Technical Sentiment Signal: Buy

Current Market Cap: $2.24B

For detailed information about PAHC stock, go to TipRanks’ Stock Analysis page.